aki

AKI-001 is a potent Aurora kinase inhibitor, which exhibits low nanomolar potency against both Aurora A and Aurora B enzymes, excellent cellular potency (IC50 < 100 nM), and good oral bioavailability. Phenotypic cellular assays show that both Aurora A and Aurora B are inhibited at inhibitor concentrations sufficient to block proliferation. Importantly, the cellular activity translates to potent inhibition of tumor growth in vivo. An oral dose of 5 mg kg QD is well tolerated and results in near stasis (92% TGI) in an HCT116 mouse xenograft model.

Terlakiren (CP-80,794) is an orally active, potent renin inhibitor used in the study of neurological disorders related to hypertension.

Tetrakis (4-carboxyphenyl) porphyrin (TCPP) serves as a metal remover and is a fabricated three-dimensional Ru polymer complex that can be grafted on SiO2 Nb2O5 substrate and subsequently metallized to study catalytic oxidation of hydrazine.

Jasplakinolide(Jaspamide), a naturally occurring cyclic peptide from marine sponges, is a potent inducer of actin polymerization.Jasplakinolide exhibits antifungal and antitumor activity and stabilizes pre-existing actin filaments. Jasplakinolide competitively binds to F-actin with the ghost pen cyclic peptide and has a Kd value of 15 nM for F-actin.

Takinib (EDHS-206) is a specific and effective TAK1 inhibitor(IC50= 9.5 nM).

AKI603 is a novel small molecule inhibitor of Aurora kinase A (AurA)(IC50 = 12.3 nM). AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells[1][2].

Anakinra (Raleukin) is a cytokine inactivator and interleukin 1 receptor antagonist that can be used to study secondary phagocytic lymphohistiocytosis and rheumatoid arthritis.

Kakisaponin A is a useful organic compound for research related to life sciences. The catalog number is T126551 and the CAS number is 1003864-78-5.

D-myo-Inositol-1,3,4,5-tetrakisphosphate potassium enhances extracellular calcium (Ca2+) influx by upregulating voltage-gated calcium channels.

Karakin is a group of plant growth regulators.

Locustakinin is a myotropic peptide.

Misakimycin is a mammalian cell growth stimulating substance produced by Streptomyces misakiensis BP-3621.

Makisterone A is an ecdysteroid that drives molting in insects. It binds the heterodimeric ecdysone receptor with nanomolar affinity.

2,4,5,6-Tetrakis(diphenylamino)isophthalonitrile is a useful organic compound for research related to life sciences and the catalog number is T64631.

4,4′,4″,4″′-(Porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) is a useful organic compound for research related to life sciences and the catalog number is T65464.

sodium tetrakis (pentafluorophenyl)-borate is a useful organic compound for research related to life sciences and the catalog number is T66574.

Octakis-(6-bromo-6-deoxy)-γ-cyclodextrin (catalog number T66647) is a valuable organic compound utilized in life sciences research.

Tetrakis[(S)-(+)-(1-adamantyl)-(N-phthalimido)acetato]dirhodium(II) is a useful organic compound for research related to life sciences. The catalog number is T67239 and the CAS number is 909389-99-7.

Ranakinin is a novel tachykinin receptor agonist; from the brain of frog, Rana ridibunda.

Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.

1,1′,1′′,1′′′-[1,4-Piperazinediylbis(2,1-ethanediylnitrilo)]tetrakis[2-dodecanol], a lipid lipidoid, is used in the synthesis of lipid-based or lipidoid nanoparticles [1].

Contulakin G, an O-glycosylated invertebrate neurotensin, serves as a weaker agonist for the neurotensin receptor. Additionally, it is recognized as a potent antinociceptive agent [1] [2].

Clazakizumab, a monoclonal antibody, demonstrates high affinity and specificity towards the interleukin-6 (IL-6) cytokine, potentially inhibiting the cytokine response in COVID-19 caused by SARS-CoV-2. It is also under research for treating psoriatic arthritis (PsA) and renal antibody-mediated rejection [1] [2].

Fezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related conditions such as psoriasis, rheumatoid arthritis and atopic dermatitis.